AbCellera Biologics Inc. Common Shares

ABCL trades with a scorching 74.9 RSI—deep into overbought territory—despite sitting 32% below its 52-week high, a disconnect that suggests either explosive momentum masking fundamental weakness or a stock caught between competing narratives. The 20.25% short interest creates meaningful squeeze potential, particularly if biotech sentiment shifts positive, yet the absence of a P/E ratio flags profitability concerns that shorts may be correctly exploiting. The $1.6B market cap positions this as a speculative biotech play where technical extremes can reverse violently. Current setup appears fragile: overbought conditions paired with unresolved cash generation questions and substantial short positioning creates a potential catalyst minefield rather than a stable foundation.